Payment overview · 2025
General Payments
$1,631.21
78 reported records · 30 companies
Healthcare provider profile · identity verified
Gregory J Oakhill, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · FAYETTEVILLE, AR · NPI 1356312466
Verified facts
What the public records show
CMS Open Payments records show Gregory J Oakhill, M.D. received $1,631.21 in general payments during 2025 across 78 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Imbruvica by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Tagrisso by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XALKORI as an associated drug or biological on 12 records involving 10 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xalkori by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xtandi by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ALUNBRIG as an associated drug or biological on 1114 records involving 827 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Alunbrig by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $382.05 | 23.4% | 14 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $162.05 | 9.9% | 8 | 2025 |
| SANOFI US SERVICES INC. | Unresolved — no canonical attribution shown | $121.20 | 7.4% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $91.42 | 5.6% | 4 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $76.91 | 4.7% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $69.64 | 4.3% | 4 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $64.22 | 3.9% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $61.61 | 3.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $57.05 | 3.5% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $52.31 | 3.2% | 3 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.82 | 3.0% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $49.22 | 3.0% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $47.80 | 2.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.30 | 2.2% | 2 | 2025 |
| Iovance Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $31.96 | 2.0% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $30.28 | 1.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.57 | 1.8% | 2 | 2025 |
| Nuvation Bio Inc. | Unresolved — no canonical attribution shown | $27.63 | 1.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.36 | 1.3% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $19.59 | 1.2% | 1 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $18.71 | 1.1% | 1 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.27 | 1.1% | 1 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $16.97 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.03 | 0.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.98 | 0.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.12 | 0.9% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $13.76 | 0.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $13.46 | 0.8% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $13.46 | 0.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $13.46 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,537.02 | 76 |
| Education | $94.19 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $348.47 | 12 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $162.05 | 8 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological, Drug | Blueprint Medicines Corporation, GENZYME CORPORATION, SANOFI US SERVICES INC. | $156.11 | 3 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $89.17 | 4 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $61.61 | 3 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $53.46 | 3 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $49.22 | 3 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $48.87 | 3 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $47.80 | 3 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $35.30 | 2 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $35.30 | 2 | 2025 |
Source payment records
|
|||||
| Amtagvi Normalized: amtagvi |
Drug | Iovance Biotherapeutics, Inc. | $31.96 | 2 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $30.28 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $29.33 | 2 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $28.57 | 2 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $28.57 | 2 | 2025 |
Source payment records
|
|||||
| ZIIHERA Normalized: ziihera |
Drug | JAZZ PHARMACEUTICALS INC. | $28.04 | 2 | 2025 |
Source payment records
|
|||||
| IBTROZI Normalized: ibtrozi |
Drug | Nuvation Bio Inc. | $27.63 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XALKORI open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 10 recipient NPIs · example record 1229104175 |
Xalkori · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | ALUNBRIG open payments reported associated product |
CMS Open Payments — General Payments 1114 supporting records · 827 recipient NPIs · example record 1223616816 |
Alunbrig · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 58 |
| Potassium Chloride | Potassium Chloride | 168 | 53 |
| Ondansetron Odt | Ondansetron | 120 | 83 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 91 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 45 |
| Letrozole | Letrozole | 80 | 26 |
| Levofloxacin | Levofloxacin | 80 | 72 |
| Eliquis | Apixaban | 73 | 15 |
| Xarelto | Rivaroxaban | 73 | 13 |
| Prednisone | Prednisone | 69 | 40 |
| Warfarin Sodium | Warfarin Sodium | 60 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 42 |
| Hydrocortisone | Hydrocortisone | 50 | 13 |
| Amlodipine Besylate | Amlodipine Besylate | 46 | 13 |
| Olanzapine | Olanzapine | 43 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 40 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 14 |
| Gabapentin | Gabapentin | 38 | 11 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 38 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 35 | 24 |
| Allopurinol | Allopurinol | 33 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 29 | suppressed |
| Anastrozole | Anastrozole | 27 | 12 |
| Fentanyl | Fentanyl | 25 | 15 |
| Lorazepam | Lorazepam | 25 | 13 |
| Dexamethasone | Dexamethasone | 23 | 18 |
| Imatinib Mesylate | Imatinib Mesylate | 23 | suppressed |
| Revlimid | Lenalidomide | 23 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 22 | suppressed |
| Omeprazole | Omeprazole | 22 | suppressed |
| Xtandi | Enzalutamide | 22 | suppressed |
| Tagrisso | Osimertinib Mesylate | 21 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 19 | 19 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Hydroxyurea | Hydroxyurea | 19 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Losartan Potassium | Losartan Potassium | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 14 |
| Imbruvica | Ibrutinib | 16 | suppressed |
| Lisinopril | Lisinopril | 16 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Furosemide | Furosemide | 14 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Alunbrig | Brigatinib | 12 | suppressed |
| Mekinist | Trametinib Dimethyl Sulfoxide | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 12 | suppressed |
| Tafinlar | Dabrafenib Mesylate | 12 | suppressed |
| Xalkori | Crizotinib | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,631.21 · 78 records | AstraZeneca Pharmaceuticals LP | ADCETRIS, AYVAKIT, Amtagvi, CABOMETYX, CARVYKTI, DATROWAY, Doptelet, ELAHERE, ELREXFIO, ENHERTU, Fabhalta, HYQVIA, IBTROZI, IMFINZI, JAYPIRCA, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LIBTAYO, LYNPARZA, Lenvima, OJJAARA, ORGOVYX, Onivyde, PROVENGE, RYBREVANT, RYTELO, SARCLISA, SCEMBLIX, TEVIMBRA, Tecentriq, Trodelvy, VERZENIO, ZEPZELCA, ZIIHERA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error